News & Events

< Back to News Overview

Viveve Announces Distribution Partnerships for Taiwan and Thailand

27 / 05 / 2015

Viveve(R) Treatment Now Available in 24 Countries Throughout the World

SUNNYVALE, CA -- (Marketwired) -- 05/27/15 -- Viveve Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women's health, today announced it has entered into distribution agreements with Dynamic Medical Technologies, Inc. ("DMT") and Beamed Co. Ltd. ("Beamed"), for the distribution of the Viveve System for the treatment of vaginal laxity. DMT and Beamed are premier distributors of medical devices based in Taichung City, Taiwan and Bangkok, Thailand respectively.

The company now has exclusive distribution partnerships covering 24 countries throughout the world:

 REGION                 COUNTRIES                         

North America                     Canada

                                 

Europe                                  United Kingdom, Ireland, Spain, The Netherlands, Belgium, Luxembourg

                                 

Asia Pacific                          Japan, Singapore, Malaysia, Vietnam, Brunei, Taiwan, Thailand

                                 

Middle East                           United Arab Emirates, Saudi Arabia, Lebanon, Kuwait, Bahrain, Qatar, Oman, Jordan, Iraq, Egypt

"We're thrilled to be working with two such highly qualified distributors to bring the globally patented Viveve System to Thailand and Taiwan. We look forward to working with both organizations to seek regulatory approval and ultimately launch the product," said Patricia Scheller, the Chief Executive Officer of Viveve. "We believe that the medical condition of vaginal laxity remains ineffectively addressed for millions of women worldwide, and that there is pent-up demand for a safe and painless in-office treatment. Having strong partners like DMT and Beamed introduce the procedure into their countries will help to ensure that physicians receive the best possible training and support as they begin offering the treatment," said Patricia Scheller, the Chief Executive Officer of Viveve.

Beamed is focused on introducing innovative, clinically proven medical technology through multi-disciplinary teams of highly trained specialists. With its broad range of knowledgeable and specialized personnel it is considered by many customers to be the leading medical device distributor in Thailand.

DMT, the market leader in the sale, maintenance and integrated marketing of energy-based medical devices in Taiwan, has a workforce of 105 experienced and motivated staff. With an emphasis on introducing novel equipment, and on providing excellent maintenance and marketing support, they have earned a distinguished reputation with both suppliers and customers.

About Viveve

Viveve, Inc., the operating subsidiary of Viveve Medical, Inc., is a women's health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The company's lead product, the globally patented Viveve® System, is a non-surgical, non-ablative medical device that remodels collagen and restores tissue with only one treatment session. The Viveve System treats the condition of vaginal laxity, which is the result of the over-stretching of tissue during childbirth that can result in a decrease in physical sensation and sexual satisfaction. Physician surveys indicate that vaginal laxity is the number one post-delivery physical change for women, being more prevalent than weight gain, urinary incontinence or stretch marks. The Viveve Treatment uses patented, reverse-thermal gradient radiofrequency technology to tighten vaginal tissue in one 30-minute out-patient treatment in a physician's office. The Viveve System has received regulatory approval in Europe, Canada and Hong Kong and is available through physician import license in Japan. It is currently not available for sale in the U.S. For more information, please visit Viveve's website at www.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are to be detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Viveve is a registered trademark of Viveve, Inc.

 

Contact:

Amato and Partners, LLC

Investor Relations Counsel

90 Park Avenue. 17th Floor

New York, NY 10016

212.430.0360

admin@amatoandpartners.com

 

Source: Viveve Medical, Inc.

Released May 27, 2015